Evaluation of Drug Therapy in Non-Communicable Diseases; a Review Study

Hamid Mirjalili, Hadis Amani, Afsaneh Ismaili, Maryam Milani Fard, A. Abdolrazaghnejad
{"title":"Evaluation of Drug Therapy in Non-Communicable Diseases; a Review Study","authors":"Hamid Mirjalili, Hadis Amani, Afsaneh Ismaili, Maryam Milani Fard, A. Abdolrazaghnejad","doi":"10.26655/jmchemsci.2022.2.8","DOIUrl":null,"url":null,"abstract":"This study is a conceptual review. Various protocols have been proposed for non-communicable diseases worldwide. The importance of this large group of diseases has prompted the World Health Organization (WHO) to plan effectively to set targets to reduce mortality from these diseases by one-third by 2030 in the Sustainable Development Plan. In asthma, corticosteroids are still recognized as the most potent anti-asthma drugs, and there is still no drug with the same effect, and biological agents (drugs such as amalizumab) significantly improve the management of severe asthma. Regarding diabetes, the recommendations of the WHO were reviewed, and the first recommendation is that if metformin, which is recommended as the first oral antidiabetic drug in all guidelines, cannot control hyperglycemia, sulfonylurea should be prescribed to patients with type 2 diabetes. Non-communicable diseases in Iran cause 45% of the disease burden in men and 33% of the disease burden in women, of the total causes of the disease burden in both sexes (6-10). Obesity and overweight, arterial hypertension, inadequate physical activity and addiction are 86% of the risk factors for diseases and 11% of all diseases. These risk factors have caused 6.1 million years of adapted life expectancy in Iran.","PeriodicalId":16365,"journal":{"name":"Journal of Medicinal and Chemical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal and Chemical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26655/jmchemsci.2022.2.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

This study is a conceptual review. Various protocols have been proposed for non-communicable diseases worldwide. The importance of this large group of diseases has prompted the World Health Organization (WHO) to plan effectively to set targets to reduce mortality from these diseases by one-third by 2030 in the Sustainable Development Plan. In asthma, corticosteroids are still recognized as the most potent anti-asthma drugs, and there is still no drug with the same effect, and biological agents (drugs such as amalizumab) significantly improve the management of severe asthma. Regarding diabetes, the recommendations of the WHO were reviewed, and the first recommendation is that if metformin, which is recommended as the first oral antidiabetic drug in all guidelines, cannot control hyperglycemia, sulfonylurea should be prescribed to patients with type 2 diabetes. Non-communicable diseases in Iran cause 45% of the disease burden in men and 33% of the disease burden in women, of the total causes of the disease burden in both sexes (6-10). Obesity and overweight, arterial hypertension, inadequate physical activity and addiction are 86% of the risk factors for diseases and 11% of all diseases. These risk factors have caused 6.1 million years of adapted life expectancy in Iran.
非传染性疾病药物治疗评价;回顾研究
本研究是一项概念回顾。世界范围内针对非传染性疾病提出了各种议定书。这一大群疾病的重要性促使世界卫生组织(世卫组织)进行有效规划,以便在《可持续发展计划》中制定目标,到2030年将这些疾病的死亡率降低三分之一。在哮喘中,皮质类固醇仍被认为是最有效的抗哮喘药物,目前仍没有药物具有相同的效果,生物制剂(阿玛珠单抗等药物)可显著改善重症哮喘的管理。关于糖尿病,我们回顾了WHO的建议,第一个建议是,在所有指南中,二甲双胍都被推荐作为第一种口服降糖药,如果二甲双胍不能控制高血糖,那么2型糖尿病患者应该开磺脲类药物。在伊朗,非传染性疾病占男性疾病负担的45%,占女性疾病负担的33%,占两性疾病负担的总原因(6-10)。肥胖和超重、动脉高血压、身体活动不足和成瘾占疾病风险因素的86%,占所有疾病的11%。这些风险因素导致伊朗人的预期寿命达到610万年。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信